STAAR SURGICAL COMPANY

NASDAQ: STAA (STAAR Surgical Company)

Last update: 2 days ago, 6:29AM

19.04

-0.07 (-0.37%)

Previous Close 19.11
Open 19.09
Volume 893,356
Avg. Volume (3M) 1,340,614
Market Cap 939,927,744
Price / Earnings (Forward) 50.25
Price / Sales 4.10
Price / Book 2.67
52 Weeks Range
13.50 (-29%) — 30.81 (61%)
Earnings Date 5 Nov 2025
Profit Margin -25.46%
Operating Margin (TTM) -81.43%
Diluted EPS (TTM) -1.44
Quarterly Revenue Growth (YOY) -44.90%
Quarterly Earnings Growth (YOY) 107.20%
Total Debt/Equity (MRQ) 10.48%
Current Ratio (MRQ) 4.78
Operating Cash Flow (TTM) -11.69 M
Levered Free Cash Flow (TTM) 10.73 M
Return on Assets (TTM) -5.90%
Return on Equity (TTM) -19.14%

Market Trend

Short Term Medium Term
Industry Medical Instruments & Supplies (US) Bullish Mixed
Medical Instruments & Supplies (Global) Bullish Bearish
Stock STAAR Surgical Company Bearish Bullish

AIStockmoo Score

-1.8
Analyst Consensus 1.0
Insider Activity NA
Price Volatility -2.0
Technical Moving Averages -3.5
Technical Oscillators -2.5
Average -1.75

Similar Stocks

Stock Market Cap DY P/E (TTM) P/B
STAA 940 M - - 2.67
MMSI 5 B - 44.30 3.20
ATRC 2 B - - 4.08
LMAT 2 B 0.94% 36.64 5.13
AZTA 2 B - 63.00 1.07
PLSE 970 M - - 11.03

Staar Surgical Co is a manufacturer of lenses. It designs, develops, manufactures, and sells implantable lenses for the eye and delivery systems used to deliver the lenses into the eye. The company also makes lenses that are used in surgery to treat cataracts. The company offers two types of products: Implantable Collamer lenses (ICL) and intraocular lens (IOL). The ICLs are used in refractive surgery and IOLs are used in cataract surgery. The majority of sales are generated from the ophthalmic surgical product segment.

Sector Healthcare
Industry Medical Instruments & Supplies
Investment Style Small Growth
% Held by Insiders 0.64%
% Held by Institutions 109.43%

Ownership

Name Date Shares Held
Broadwood Capital Inc 30 Sep 2025 13,519,491
Yunqi Capital Ltd 30 Sep 2025 2,500,061
Sand Grove Capital Management Llp 30 Sep 2025 829,123
American Capital Management Inc 30 Sep 2025 743,424
Defender Capital, Llc. 31 Dec 2025 668,222
Water Island Capital Llc 30 Sep 2025 658,317
52 Weeks Range
13.50 (-29%) — 30.81 (61%)
Price Target Range
21.50 (12%) — 30.75 (61%)
High 30.75 (Wells Fargo, 61.50%) Hold
Median 22.00 (15.55%)
Low 21.50 (Jefferies, 12.92%) Buy
Average 24.75 (29.99%)
Total 1 Buy, 2 Hold
Avg. Price @ Call 21.33
Firm Date Target Price Call Price @ Call
Jefferies 28 Jan 2026 21.50 (12.92%) Buy 19.04
Canaccord Genuity 16 Jan 2026 22.00 (15.55%) Hold 20.97
10 Dec 2025 30.75 (61.50%) Hold 23.99
Wells Fargo 10 Dec 2025 30.75 (61.50%) Hold 23.99

No data within this time range.

Date Type Details
15 Jan 2026 Announcement STAAR Surgical and Broadwood Partners Enter Into Cooperation Agreement
06 Jan 2026 Announcement Alcon Terminates Agreement to Acquire STAAR Surgical
06 Jan 2026 Announcement Broadwood Partners Comments on STAAR Surgical Shareholders’ Rejection of the Company’s Proposed Sale to Alcon
06 Jan 2026 Announcement STAAR Surgical Announces Preliminary Results of Special Meeting of Stockholders
19 Dec 2025 Announcement Broadwood Partners Denounces STAAR Surgical’s Fourth Delay of the Shareholder Vote on the Company’s Proposed Sale to Alcon
19 Dec 2025 Announcement Alcon Exercises Right to Require STAAR Surgical to Adjourn its Special Meeting of Stockholders
17 Dec 2025 Announcement Defender Capital Reiterates Intention to Vote AGAINST STAAR Surgical's Proposed Sale to Alcon Inc.
17 Dec 2025 Announcement Broadwood Partners Issues Open Letter to STAAR Surgical Board Pledging Cooperation and Support When Vote on Alcon Transaction Fails
17 Dec 2025 Announcement STAAR Stockholders Have a Choice: Vote FOR Alcon’s Certain, Premium $30.75 Per Share Cash Offer or Bear the Downside Risk that Broadwood Has No Credible Plan to Create Stockholder Value
16 Dec 2025 Announcement Yunqi Capital Comments on Proxy Advisors’ Updated Recommendations, Urges Shareholders to Continue to Back the Company’s Standalone Trajectory
16 Dec 2025 Announcement Independent Industry Analysts Recognize Value Provided to STAAR Stockholders by Amended Alcon Merger Agreement and Merits of Alcon Transaction
16 Dec 2025 Announcement Broadwood Partners Comments on ISS Report on Proposed Sale of STAAR Surgical to Alcon
15 Dec 2025 Announcement Leading Independent Proxy Advisory Firm ISS Recommends STAAR Stockholders Vote “FOR” Alcon Merger
12 Dec 2025 Announcement Broadwood Partners: Leading Proxy Advisory Firm Glass Lewis Reaffirms Recommendation “AGAINST” STAAR Surgical Sale to Alcon
11 Dec 2025 Announcement Broadwood Partners Comments on STAAR Surgical Board Dissent on the Revised Sale to Alcon
11 Dec 2025 Announcement STAAR Surgical Sets the Record Straight Regarding its Robust Go-Shop Process
10 Dec 2025 Announcement Yunqi Capital Comments on STAAR Surgical’s Go-Shop Process and Alcon’s Revised Offer
09 Dec 2025 Announcement Broadwood Partners Responds to Alcon’s Increase to Proposed Acquisition Price of STAAR Surgical
09 Dec 2025 Announcement Alcon Announces Amended Merger Agreement with STAAR Surgical
08 Dec 2025 Announcement Broadwood Partners Reiterates Opposition to STAAR Surgical’s Sale to Alcon Following Conclusion of Performative Go-Shop Process
08 Dec 2025 Announcement Broadwood Partners: Proxy Advisory Firm Egan-Jones Reaffirms Its Recommendation STAAR Surgical Shareholders Vote “AGAINST” Sale to Alcon
08 Dec 2025 Announcement STAAR Surgical Announces Expiration of Go-Shop Period
02 Dec 2025 Announcement Broadwood Partners Working to Call Special Meeting of STAAR Surgical Shareholders to Remove Three Directors
10 Nov 2025 Announcement Broadwood Partners Calls for the Appointment of New Directors at STAAR Surgical to Oversee Go-Shop Process
07 Nov 2025 Announcement STAAR Surgical Announces Amendments to Alcon Merger Agreement
06 Nov 2025 Announcement Yunqi Capital Applauds STAAR Surgical’s Strong Third Quarter Results and Reiterates That the Proposed Sale to Alcon Should Be Terminated
05 Nov 2025 Announcement STAAR Surgical Reports Third Quarter 2025 Results
04 Nov 2025 Announcement Broadwood Partners Condemns Alcon’s Fallacious Attacks on STAAR Surgical and Its Prospects
04 Nov 2025 Announcement Alcon Releases Investor Discussion Materials Reinforcing Certain Value of Merger Proposal for STAAR Stockholders
31 Oct 2025 Announcement Yunqi Capital Issues Letter to STAAR Surgical Board Calling for Termination of the Proposed Merger with Alcon
Show more

The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.

Portfolio

AI Template

Your price alert

Risk Profile

| | | | |
Conservative
Moderate Conservative
Moderate
Moderate Aggressive
Aggressive
Margin of Safety (EP)
Partial Profit (TP1)
Target Profit (TP2)
Maximum Loss (SL)

Disclaimer: The above is for illustrative purposes only and is NOT investment advice. Seek advice from a qualified financial professional.

Entry Price (EP)

Take Profit 1 (TP1)

Take Profit 2 (TP2)

Stop Loss (SL)

52W Range
 
52WL
 
52WH
SL
EP
TP1
TP2

All alert prices are within 52 weeks price range

Realized Profit -
Unrealized Profit -
Dividend Received 2026 -
Total Profit -
Avg. Return -
Quantity (Buy) -
Avg. Price (Buy) -
Quantity (Sold) -
Avg. Price (Sold) -
No stocks matching your criteria